Drug Profile
Research programme: recombinant human MASP-2 - Helion Biotech
Latest Information Update: 30 Nov 2010
Price :
$50
*
At a glance
- Originator Helion Biotech
- Class Recombinant proteins
- Mechanism of Action MASP2 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Infections
Most Recent Events
- 30 Nov 2010 Discontinued - Preclinical for Infections in Denmark (Parenteral)
- 12 Nov 2008 This programme is available for licensing (http://www.helionbiotech.com)
- 12 Nov 2008 Preclinical trials in Infections in Denmark (Parenteral)